ClinicalTrials.gg
CompletedNCT00561470VELOURUpdated Sep 28, 2012Results posted

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

A Phase 3 interventional study of Placebo and Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Colorectal Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 221 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,226
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
Largest of 24
1,226 · median 63
Started
2007
the only one that year
Phase 3
4 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one has the largest enrollment, is the only one that started in 2007, is one of 4 in phase 3, and was the 1st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease.

The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.

Read the detailed description

Participants were

  • randomized at baseline (treatment was initiated with 3 days of randomization)
  • administered treatment in cycles of 14-days till a study withdrawal criterion was met
  • followed up 30 days after discontinuation of treatment, and every 8 weeks until death or end of study.

The criteria for discontinuation of study treatment for a participant are:

  • participant (or legal representative) chose to withdraw from treatment
  • the investigator thought that continuation of the study would be detrimental to the participants well-being due to

    • disease progression
    • unacceptable AEs
    • intercurrent illnesses
    • non-compliance to the study protocol
  • participant was lost to follow-up
  • participant was unblinded for the investigational treatment
03

Conditions studied

  • Colorectal Neoplasms
  • Neoplasm Metastasis

Keywords

  • colorectal cancer
  • metastatic
  • anti-angiogenic
  • irinotecan
  • 5-FU
  • FOLFIRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants who met the following main selection criteria were included in the study.

Inclusion criteria

Inclusion Criteria:

  • or cytologically proven adenocarcinoma of the colon or rectum
  • disease that is not amenable to potentially curative treatment
  • One and only one for metastatic disease. This prior line should be an oxaliplatin based chemotherapy (participants who relapse within 6 months of completion of oxaliplatin based chemotherapy are eligible)
  • Prior treatment with bevacizumab is permitted.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with irinotecan
  • performance status >2

The above information is not intended to contain all considerations relevant to participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,226 participants (actual)

Study arms

  • Placebo comparator
    Placebo/FOLFIRI

    Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met

    Drug: Placebo · Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

  • Experimental
    Aflibercept/FOLFIRI

    Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

Interventions

  • DrugPlacebo

    4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks

  • 4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.

  • DrugFOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

    The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours

  • DrugFOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

    The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011). OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.

    Time frame: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)

Secondary outcomes

  1. Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

    PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC. PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model. The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred.

    Time frame: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)

  2. Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

    The overall ORR was the percentage of evaluable participants who achieved complete response \[CR\] or partial response \[PR\] according to RECIST criteria version 1.0. * CR reflected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined reduction in tumor burden Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.

    Time frame: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)

  3. Number of Participants With Adverse Events (AE)

    All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

    Time frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

  4. Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

    Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay.

    Time frame: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo

07

Results

Posted Sep 28, 2012

Participant flow

Between 19 November 2007 and 16 March 2010, 614 participants were randomized to the placebo arm and 612 participants were randomized to the aflibercept arm.

Participant flow — Overall Study
MilestonePlacebo/FOLFIRIAflibercept/FOLFIRI
Started614612
Treated609607
Safety population605611
Ongoing treatment1114
Completed00
Not completed614612
Withdrew: Adverse event74163
Withdrew: Disease progression437305
Withdrew: Poor compliance to protocol44
Withdrew: Lost to follow-up20
Withdrew: Physician decision2120
Withdrew: Consent withdrawn26
Withdrew: Subject request4377
Withdrew: Metastatic surgery1012
Withdrew: Unauthorized procedure31
Withdrew: Randomized but not treated55
Withdrew: Missed visit window14
Withdrew: Planning surgery11
Withdrew: Ongoing treatment1114

Outcome measures

PrimaryOverall Survival (OS)

Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011). OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.

Time frame:
From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo/FOLFIRIAflibercept/FOLFIRI
Overall Survival (OS)12.06 (6.83 to 21.03)13.50 (7.62 to 25.59)
Statistical analysis
  • Placebo/FOLFIRI vs Aflibercept/FOLFIRI · Stratified Log-Rank test · p = 0.0032 (Stratified Log-Rank test p-value. Stratified on ECOG Performance Status and prior Bevacizumab according to IVRS using the Cox Proportional Hazard Model. Significance threshold was set to 0.0466 using the O'Brien-Fleming alpha spending function.) · Stratified hazard ratio: 0.817 · 95.34% CI 0.713 to 0.937Stratified on ECOG Performance Status (0 vs 1 vs 2) and prior Bevacizumab (yes vs no) according to IVRS using the Cox Proportional Hazard Model. Significance threshold was set to 0.0466 using the O'Brien-Fleming alpha spending function.
SecondaryProgression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC. PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model. The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred.

Time frame:
From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
Reported as:
Median · months
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
monthsPlacebo/FOLFIRIAflibercept/FOLFIRI
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)4.67 (2.60 to 9.10)6.90 (3.84 to 10.05)
Statistical analysis
  • Placebo/FOLFIRI vs Aflibercept/FOLFIRI · Stratified Log-Rank test · p = 0.00007 (Stratified on ECOG Performance Status (0 vs 1 vs 2) and prior Bevacizumab (yes vs no) according to IVRS) · Stratified hazard ratio: 0.758 · 99.99% CI 0.578 to 0.995Stratified on ECOG Performance Status (0 vs 1 vs 2) and prior Bevacizumab (yes vs no) according to IVRS using the Cox Proportional Hazard Model.
SecondaryOverall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

The overall ORR was the percentage of evaluable participants who achieved complete response \[CR\] or partial response \[PR\] according to RECIST criteria version 1.0. * CR reflected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined reduction in tumor burden Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.

Time frame:
From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
Reported as:
Number · percentage of participants
Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
percentage of participantsPlacebo/FOLFIRIAflibercept/FOLFIRI
Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria11.1 (8.5 to 13.8)19.8 (16.4 to 23.2)
Statistical analysis
  • Placebo/FOLFIRI vs Aflibercept/FOLFIRI · Stratified Cochran-Mantel-Haenszel · p = 0.0001Stratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS.
SecondaryNumber of Participants With Adverse Events (AE)

All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

Time frame:
From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
Reported as:
Number · participants
Number of Participants With Adverse Events (AE)
participantsPlacebo/FOLFIRIAflibercept/FOLFIRI
Treatment-Emergent Adverse Event (TEAE)592606
Serious TEAE198294
TEAE leading to Death2937
TEAE causing permanent treatment discontinuation73164
SecondaryImmunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay.

Time frame:
Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
Reported as:
Number · participants
Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
participantsPlacebo/FOLFIRIAflibercept/FOLFIRI
At least one positive sample in the ADA assay188
At least one positive sample in the NAb assay21

Adverse events

Collected over From treatment initiation to 7 February, 2011. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/FOLFIRI—198/605 (32.7%)575/605 (95%)
Aflibercept/FOLFIRI—294/611 (48.1%)599/611 (98%)
Most frequent serious events
Showing 10 of 252
Most frequent serious events
EventPlacebo/FOLFIRIAflibercept/FOLFIRI
DiarrhoeaGastrointestinal disorders14/60544/611
DehydrationMetabolism and nutrition disorders7/60524/611
Febrile neutropeniaBlood and lymphatic system disorders6/60519/611
Pulmonary embolismRespiratory, thoracic and mediastinal disorders12/60519/611
Disease progressionGeneral disorders14/60516/611
PyrexiaGeneral disorders15/60510/611
Abdominal painGastrointestinal disorders7/60512/611
Intestinal obstructionGastrointestinal disorders11/60510/611
PneumoniaInfections and infestations5/60511/611
NeutropeniaBlood and lymphatic system disorders4/60511/611
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlacebo/FOLFIRIAflibercept/FOLFIRI
DiarrhoeaGastrointestinal disorders335/605411/611
NauseaGastrointestinal disorders327/605322/611
StomatitisGastrointestinal disorders199/605304/611
FatigueGeneral disorders234/605292/611
HypertensionVascular disorders65/605250/611
NeutropeniaBlood and lymphatic system disorders202/605229/611
VomitingGastrointestinal disorders199/605194/611
Decreased appetiteMetabolism and nutrition disorders143/605195/611
Weight decreasedInvestigations87/605195/611
AlopeciaSkin and subcutaneous tissue disorders182/605164/611

Baseline characteristics

Age Continuous
Age Continuous(years)Placebo/FolfiriAflibercept/FolfiriTotal
Mean60.2 ± 10.859.5 ± 10.559.8 ± 10.7
Age, Customized
Age, Customized(participants)Placebo/FolfiriAflibercept/FolfiriTotal
<65 years376407783
>=65 but <75 years199172371
>=75 years393372
Sex/Gender, Customized
Sex/Gender, Customized(participants)Placebo/FolfiriAflibercept/FolfiriTotal
Male353365718
Female261247508
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo/FolfiriAflibercept/FolfiriTotal
Caucasian/White5235481071
Black271643
Asian/Oriental513586
Other131326
Region of Enrollment
Region of Enrollment(participants)Placebo/FolfiriAflibercept/FolfiriTotal
ARGENTINA426
AUSTRALIA425496
AUSTRIA347
BELGIUM374582
BRAZIL212748
CHILE313364
CZECH REPUBLIC304777
DENMARK9615
ESTONIA7310
FRANCE112
GERMANY231235
GREECE91019
ITALY262349
KOREA, REPUBLIC OF392665
NETHERLANDS201434
NEW ZEALAND13720
NORWAY141933
POLAND243256
PUERTO RICO426
ROMANIA161632
RUSSIAN FEDERATION354075
SOUTH AFRICA363167
SPAIN272855
SWEDEN10414
TURKEY426
UKRAINE111122
UNITED KINGDOM475299
UNITED STATES7161132
Eastern Cooperative Oncology Group (ECOG) performance status score
Eastern Cooperative Oncology Group (ECOG) performance status score(participants)Placebo/FolfiriAflibercept/FolfiriTotal
Participants with ECOG Score = 0350349699
Participants with ECOG Score = 1250250500
Participants with ECOG Score = 2141327
Prior Bevacizumab
Prior Bevacizumab(participants)Placebo/FolfiriAflibercept/FolfiriTotal
Yes187186373
No427426853
08

Study locations

221 sites
  • Sanofi-Aventis Investigational Site Number 840119
    Birmingham, Alabama 35203, United States
  • Sanofi-Aventis Investigational Site Number 840074
    Muscle Shoals, Alabama 35661, United States
  • Sanofi-Aventis Investigational Site Number 840093
    Hot Springs, Arizona 71913, United States
  • Sanofi-Aventis Investigational Site Number 840080
    Anaheim, California 92801, United States
  • Sanofi-Aventis Investigational Site Number 840076
    Fountain Valley, California 92708, United States
  • Sanofi-Aventis Investigational Site Number 840120
    Fountain Valley, California 92708, United States
  • Sanofi-Aventis Investigational Site Number 840073
    Greenbrae, California 94904-2007, United States
  • Sanofi-Aventis Investigational Site Number 840101
    Hayward, California 94545, United States
  • Sanofi-Aventis Investigational Site Number 840046
    La Jolla, California 92037, United States
  • Sanofi-Aventis Investigational Site Number 840116
    Loma Linda, California 92354, United States
  • Sanofi-Aventis Investigational Site Number 840048
    Long Beach, California 90813, United States
  • Sanofi-Aventis Investigational Site Number 840201
    Oakland, California 94611, United States
  • Sanofi-Aventis Investigational Site Number 840901
    Roseville, California 95678, United States
  • Sanofi-Aventis Investigational Site Number 840042
    Sacramento, California 95816, United States
  • Sanofi-Aventis Investigational Site Number 840301
    Sacramento, California 95825, United States
  • Sanofi-Aventis Investigational Site Number 840112
    Salinas, California 93901-3906, United States
  • Sanofi-Aventis Investigational Site Number 840006
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840106
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840206
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840306
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840406
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840506
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840606
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840706
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840806
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840906
    San Diego, California 92102, United States
  • Sanofi-Aventis Investigational Site Number 840401
    San Francisco, California 94115, United States
  • Sanofi-Aventis Investigational Site Number 840601
    San Jose, California 95119, United States
  • Sanofi-Aventis Investigational Site Number 840501
    Santa Clara, California 95051, United States
  • Sanofi-Aventis Investigational Site Number 840801
    South San Francisco, California 94080, United States
  • Sanofi-Aventis Investigational Site Number 840001
    Vallejo, California 94589, United States
  • Sanofi-Aventis Investigational Site Number 840701
    Walnut Creek, California 94596, United States
  • Sanofi-Aventis Investigational Site Number 840071
    Stamford, Connecticut 06902, United States
  • Sanofi-Aventis Investigational Site Number 840014
    Newark, Delaware 19718, United States
  • Sanofi-Aventis Investigational Site Number 840089
    Boynton Beach, Florida 33435, United States
  • Sanofi-Aventis Investigational Site Number 840041
    Gainesville, Florida 32608, United States
  • Sanofi-Aventis Investigational Site Number 840031
    Gainesville, Florida 32610, United States
  • Sanofi-Aventis Investigational Site Number 840122
    Miami, Florida 33176, United States
  • Sanofi-Aventis Investigational Site Number 840079
    The Villages, Florida 32159, United States
  • Sanofi-Aventis Investigational Site Number 840087
    Chicago, Illinois 60616, United States
  • Sanofi-Aventis Investigational Site Number 840019
    Decatur, Illinois 62526, United States
  • Sanofi-Aventis Investigational Site Number 840115
    Elk Grove Village, Illinois 60007, United States
  • Sanofi-Aventis Investigational Site Number 840010
    Naperville, Illinois 60540, United States
  • Sanofi-Aventis Investigational Site Number 840113
    Quincy, Illinois 62301, United States
  • Sanofi-Aventis Investigational Site Number 840072
    Indianapolis, Indiana 46254, United States
  • Sanofi-Aventis Investigational Site Number 840047
    Indianapolis, Indiana 46260, United States
  • Sanofi-Aventis Investigational Site Number 840034
    Munster, Indiana 46321, United States
  • Sanofi-Aventis Investigational Site Number 840088
    Louisville, Kentucky 40202, United States
  • Sanofi-Aventis Investigational Site Number 840096
    Paducah, Kentucky 42003, United States
  • Sanofi-Aventis Investigational Site Number 840043
    Baton Rouge, Louisiana 70809, United States
  • Sanofi-Aventis Investigational Site Number 840084
    Metairie, Louisiana 70006, United States
  • Sanofi-Aventis Investigational Site Number 840015
    New Orleans, Louisiana 70121, United States
  • Sanofi-Aventis Investigational Site Number 840070
    Rockville, Maryland 20850, United States
  • Sanofi-Aventis Investigational Site Number 840029
    Salisbury, Maryland 21801, United States
  • Sanofi-Aventis Investigational Site Number 840053
    Pontiac, Michigan 48341, United States
  • Sanofi-Aventis Investigational Site Number 840021
    St Louis Park, Minnesota 55416, United States
  • Sanofi-Aventis Investigational Site Number 840081
    Kansas City, Missouri 64128, United States
  • Sanofi-Aventis Investigational Site Number 840052
    St Louis, Missouri 63104, United States
  • Sanofi-Aventis Investigational Site Number 840114
    St. Louis, Missouri 63136, United States
  • Sanofi-Aventis Investigational Site Number 840049
    Las Vegas, Nevada 89106, United States
  • Sanofi-Aventis Investigational Site Number 840044
    Albuquerque, New Mexico 87131, United States
  • Sanofi-Aventis Investigational Site Number 840036
    Albany, New York 12206, United States
  • Sanofi-Aventis Investigational Site Number 840094
    Lake Success, New York 11042, United States
  • Sanofi-Aventis Investigational Site Number 840017
    Syracuse, New York 13210, United States
  • Sanofi-Aventis Investigational Site Number 840097
    Syracuse, New York 13210, United States
  • Sanofi-Aventis Investigational Site Number 840035
    Burlington, North Carolina 27215, United States
  • Sanofi-Aventis Investigational Site Number 840024
    Charlotte, North Carolina 28204, United States
  • Sanofi-Aventis Investigational Site Number 840026
    Charlotte, North Carolina 28262, United States
  • Sanofi-Aventis Investigational Site Number 840005
    Goldsboro, North Carolina 27534, United States
  • Sanofi-Aventis Investigational Site Number 840004
    Hendersonville, North Carolina 28791, United States
  • Sanofi-Aventis Investigational Site Number 840075
    Winston-Salem, North Carolina 27103, United States
  • Sanofi-Aventis Investigational Site Number 840098
    Cincinnati, Ohio 45219, United States
  • Sanofi-Aventis Investigational Site Number 840011
    Kettering, Ohio 45429, United States
  • Sanofi-Aventis Investigational Site Number 840086
    Middletown, Ohio 45042, United States
  • Sanofi-Aventis Investigational Site Number 840008
    Toledo, Ohio 43623, United States
  • Sanofi-Aventis Investigational Site Number 840039
    Portland, Oregon 97227, United States
  • Sanofi-Aventis Investigational Site Number 840118
    Bethlehem, Pennsylvania 18015, United States
  • Sanofi-Aventis Investigational Site Number 840033
    Philadelphia, Pennsylvania 19107, United States
  • Sanofi-Aventis Investigational Site Number 840012
    Pittsburgh, Pennsylvania 15212, United States
  • Sanofi-Aventis Investigational Site Number 840082
    Pawtucket, Rhode Island 02860, United States
  • Sanofi-Aventis Investigational Site Number 840095
    Woonsocket, Rhode Island 02895, United States
  • Sanofi-Aventis Investigational Site Number 840085
    Charleston, South Carolina 29403, United States
  • Sanofi-Aventis Investigational Site Number 840037
    Spartanburg, South Carolina 29303, United States
  • Sanofi-Aventis Investigational Site Number 840078
    Corpus Christi, Texas 78405, United States
  • Sanofi-Aventis Investigational Site Number 840117
    Temple, Texas 76508, United States
  • Sanofi-Aventis Investigational Site Number 840099
    Seattle, Washington 98115, United States
  • Sanofi-Aventis Investigational Site Number 840002
    Marshfield, Wisconsin 54449, United States
  • Sanofi-Aventis Investigational Site Number 032003
    Bahia Blanca, 8000, Argentina
  • Sanofi-Aventis Investigational Site Number 032006
    Buenos Aires, 1426ANZ, Argentina
  • Sanofi-Aventis Investigational Site Number 032005
    Ciudad De Buenos Aires, C1426BOR, Argentina
  • Sanofi-Aventis Investigational Site Number 032007
    Salta, 4400, Argentina
  • Sanofi-Aventis Investigational Site Number 036004
    Hornsby, 2077, Australia
  • Sanofi-Aventis Investigational Site Number 036001
    Kingswood, 2747, Australia
  • Sanofi-Aventis Investigational Site Number 036002
    Kurralta Park, 5037, Australia
  • Sanofi-Aventis Investigational Site Number 036005
    Melbourne, 3050, Australia
  • Sanofi-Aventis Investigational Site Number 036003
    Melbourne, 3128, Australia
  • Sanofi-Aventis Investigational Site Number 036007
    Nedlands, 6009, Australia
  • Sanofi-Aventis Investigational Site Number 036006
    Subiaco, 6008, Australia
  • Sanofi-Aventis Investigational Site Number 040001
    Wien, 1090, Austria
  • Sanofi-Aventis Investigational Site Number 056006
    Bonheiden, 2820, Belgium

Showing the first 100 of 221 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lu L, Dercle L, Zhao B, Schwartz LH. Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging. Nat Commun. 2021 Nov 17;12(1):6654. doi: 10.1038/s41467-021-26990-6. PubMed 34789774 ↗
  • Chau I, Fakih M, Garcia-Alfonso P, Linke Z, Ruiz Casado A, Marques EP, Picard P, Celanovic M, Cartwright T. Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers (Basel). 2020 Mar 11;12(3):657. doi: 10.3390/cancers12030657. PubMed 32168980 ↗
  • Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol. 2018 Jan;9(1):32-39. doi: 10.1016/j.jgo.2017.07.010. Epub 2017 Aug 12. PubMed 28807738 ↗
  • Stanel SC, Sjoberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open. 2017 May 2;2(2):e000190. doi: 10.1136/esmoopen-2017-000190. eCollection 2017. PubMed 28761750 ↗
  • Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomy R, Prausova J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kroning H, Humblet Y, Gravalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9. PubMed 26706237 ↗
  • Tabernero J, Van Cutsem E, Lakomy R, Prausova J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16. PubMed 24140268 ↗
  • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201. Epub 2012 Sep 4. PubMed 22949147 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Feb 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 7 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2007
First posted
Nov 21, 2007
Start
Nov 2007
Primary completionActual
Feb 2011
CompletionActual
Jun 2012
Results delay requested
Mar 14, 2012
Results first posted
Sep 28, 2012
Last update
Sep 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00561470
Lead sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals, NSABP Foundation Inc
Responsible party
Sponsor
First posted
Nov 21, 2007
Start date
Nov 2007
Primary completion
Feb 2011
Completion
Jun 2012
Results posted
Sep 28, 2012
Last update
Sep 28, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion